4.6 Article

Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain

期刊

ATHEROSCLEROSIS
卷 375, 期 -, 页码 38-44

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2023.04.013

关键词

Bempedoic acid; Cardiovascular; Cholesterol; Ezetimibe; PCSK9 inhibitors; Statins

向作者/读者索取更多资源

This study investigated the impact of physicians' perception about LDL-cholesterol control on the management of patients with dyslipidemia in Spain. The study found that most patients did not achieve the recommended LDLc goals due to physicians' misperception and lack of patient adherence.
Background and aims: We aimed to understand the impact of physicians' perception about LDL-cholesterol (LDLc) control on the management of patients with dyslipidemia in Spain.Methods: We performed a cross-sectional and multicenter study, in which 435 healthcare professionals partici-pated in face-to-face meetings, collecting qualitative and quantitative information related to hypercholester-olemia management. Additionally, aggregated anonymized data of the last 10 patients with hypercholesterolemia attended by each physician were collected.Results: A total of 4,010 patients (8%, 13%, 16% and 61% with low, moderate, high, and very high cardiovascular [CV] risk) were included. Physicians' perception was that 62% of their patients attained LDLc goals (66%, 63%, 61% and 56%, for low, moderate, high and very high CV risk, respectively). However, when looking into the data only 31% (vs 62% p<0.01) of patients attained the LDLc goals (47%, 36%, 22% and 25%, respectively). Overall, 33% of patients were taking high intensity statins, 32% statin/ezetimibe, 21% low/moderate intensity statins and 4% PCSK9 inhibitors. These numbers were 38%, 45%, 8% and 6% for very high risk patients and 44%, 21%, 21% and 4% for high CV risk patients. In 32% of patients, a change in lipid lowering therapy was performed after the visit, mainly combining statins/ezetimibe (55%).Conclusions: In Spain, most patients with dyslipidemia do not achieve the recommended LDLc goals because of an insufficient intensification of lipid lowering therapy. On the one hand, this is in part due to physicians misperception on preventive LDLc control and the need for repeated advice to patient, and, on the other, to the lack of patient adherence.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据